BioNotebook: Incyte, Agenus sign $410m immuno-oncology pact; plus six more deals
This article was originally published in Scrip
Executive Summary
Incyte will pay Agenus $60m up front and $350m in development, regulatory and commercial milestone fees to license the Retrocyte Display antibody discovery platform for the development of novel immunotherapies. The upfront fee is comprised of a $25m technology and program access fee as well as a $35m equity investment at $4.51 per share.
You may also be interested in...
Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.